< Return back to Press Releases
Bridge Laboratories' China Facility Receives Full AAALAC Accreditation:
First Preclinical CRO with US and China Multispecies Capabilities
Gaithersburg, MD (August 6, 2007)
Bridge Global Pharmaceuticals, Inc. (Bridge) announced the awarding of full accreditation to its facility in Beijing, China by the Council on Accreditation of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International). Bridge's facility in Beijing (Vital Bridge (China), Inc.) is one of only seven toxicology facilities in China to receive this recognition, and Bridge is the first US-based company to offer toxicology services in multispecies at both locations in the US and China. In the accreditation letter to Bridge dated June 28, 2007, AAALAC International states, "The management and staff are commended for providing quality facilities and programs for the care and use of laboratory animals. Especially noteworthy were the institution's strong administrative support for the animal care and use program as exemplified by the high quality facilities, the extensive investment in training and education of personnel, and the excellent teamwork noted among the staff [at Bridge]; as well as the extensive, well conceived, and thoroughly implemented occupational health and safety program."
Bridge's Maryland facility has long maintained AAALAC accreditation. More than 30 countries recognize AAALAC accreditation as a demonstration of responsible, ethical lab animal care. AAALAC accreditation now acknowledges that Bridge's China facility also maintains animal laboratories with the highest international standards.
Bridge's China facility was purpose built to exacting specifications (water systems, electricity, humidity control, HVAC, security, IT and data management systems) and staffed with experienced, English-speaking professionals. "Bridge has set the standard for China preclinical GLP labs," said the General Manager of Bridge's facility in Beijing. "The AAALAC site inspectors cut no corners. They evaluated our overall physical plant, our animal husbandry and housing, plus waste management, the labs, our veterinary care, our procedures (SOP's), IACUC and policies, staff training and education, our safety program—everything was scrutinized. Thanks to a great team effort and hard work by everyone, the first AAALAC site visit resulted in full accreditation. This is a monumental achievement."
"AAALAC accreditation is what Bridge clients expect," added the Bridge CEO. "They insist on preclinical drug development services that deliver superior quality scientific data. Now, whether customers choose preclinical drug development studies in our laboratories in the US or China, AAALAC accreditation assures them we will deliver data quality of the highest order."
About Pharmaron
Founded in 2003, Pharmaron is a leading pharmaceutical and biotechnology drug R&D CRO, with operations in China and the United States. Clients include pharmaceutical, biotechnology, academic and government organizations. As a research-driven and customer-focused company, Pharmaron provides a broad, integrated portfolio of laboratory and manufacturing services from drug discovery to IND submission. These services are designed to help its global partners improve the success of research and shorten the time of development cost effectively in discovering and developing drugs. For more information about Pharmaron, please visit http://www.pharmaron.com.
|
